The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

ViroPharma to Participate in Two November Healthcare Investor Conferences

Wednesday, November 02, 2011

ViroPharma to Participate in Two November Healthcare Investor Conferences12:00 EDT Wednesday, November 02, 2011EXTON, Pa., Nov. 2, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Lazard Capital Markets 8th Annual Healthcare Conference at 1:30 P.M. ET on Wednesday, November 16, 2011.  The conference is being held at the Pierre Hotel in New York City.Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Piper Jaffray 23rd Annual Healthcare Conference at 2:00 P.M. ET on Wednesday, November 30, 2011.  The conference is being held at the New York Palace Hotel.ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business. SOURCE ViroPharma IncorporatedFor further information: Robert A. Doody Jr., Assistant Director, Investor Relations, +1-610-321-6290